Haematological cancer: Deep molecular response predicts survival in CML


New research has shown that a majority of patients with chronic myeloid leukaemia (CML) who are treated with the tyrosine kinase inhibitor imatinib can achieve a deep molecular response (≥4.5-log reduction in BCR–ABL fusion gene transcript levels; MR4.5) and that MR4.5 is predictive of survival. Major molecular response (MMR; ≥3-log reduction in BCR–ABL… (More)
DOI: 10.1038/nrclinonc.2013.235